Reimagining Vaccines for Prostate Cancer: Back to the Future
Abstract
Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here, the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-2257
Entities
People
- Emmanuel S. Antonarakis
- Eugene Shenderov
Organizations
- Johns Hopkins University
- National Institutes of Health
- United States Department of Defense